Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) announced that it has been granted a patent in India (Patent no. 319759) for its WaferiX™ drug delivery technology.

EddyLee1019Eddy Lee, executive chairman of iX Biopharma at the FY19 AGM. NextInsight photo.The patent will expire on 26 October 2030.

WaferiX™ is a multiple drug carrier platform technology that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e. placed under the tongue).

The compounds are delivered safely, conveniently and rapidly into the blood stream.


Produced via the Group’s proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active molecules is designed to collapse quickly within the sublingual space.

The molecules are then transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action.

In addition, the technology has also been proven to increase the bioavailability of drug actives as well as predictability of effect.

Stock price 

21 c

52-week range

16 – 29 c

Market cap

S$135 m

PE (ttm)

-

Dividend yield 

-

Year-to-date 
return

23%

Shares outstanding

644.6 m

Source: Bloomberg

With India’s grant of patent, iX Biopharma’s intellectual property rights for its sublingual wafer technology are now secured in key Asian markets including China, Singapore, South Korea, Malaysia, Indonesia and Japan.

Apart from Asia, iX Biopharma has amassed a portfolio of patents in other countries, namely Australia, New Zealand, Canada, South Africa, United Kingdom and countries in the European Union such as Germany, France, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland, as well as Finland.

EvanTan7.19Ms Eva Tan (photo), Director, Corporate and Commercial Strategy of iX Biopharma commented:

“Moving forward, the Group will continue to leverage on the vast commercial potential of WaferiX™ to develop novel treatment options in order to satisfy unmet medical needs.

"Supported by a broad and diversified patent portfolio of major markets countries, we are well-positioned to seek out potential export opportunities for WaferiX™ products by way of off-take agreements and out-licensing, so as to diversify our revenue streams and chart new avenues of growth.”

See also: 


Share Prices

Counter NameLastChange
AEM Holdings1.820-0.030
AusGroup0.030-0.001
Avi-Tech Electronics0.375-
Best World Int.1.360-
CEI0.960-0.020
China Sunsine1.060-0.010
CNMC GoldMine0.250-0.005
CSE Global0.555-0.015
Eagle HTrust USD0.530-0.005
Food Empire0.600-0.015
Golden Energy0.165-0.004
GSS Energy0.088-0.006
ISDN Holdings0.220-0.005
ISOTeam0.2450.005
JB Foods0.650-
KSH Holdings0.455-0.020
Miyoshi0.033-0.001
Moya Asia0.066-0.001
Nordic Group0.270-
Oxley Holdings0.355-0.005
Procurri0.370-
REX International0.174-0.018
Riverstone0.9650.005
Roxy-Pacific0.4000.015
Sing Holdings0.395-0.005
SingMedical0.305-0.010
Straco Corp.0.705-0.010
Sunningdale Tech1.290-0.010
Sunpower Group0.545-0.020
The Trendlines0.0900.001
Tiong Seng0.200-0.025
Uni-Asia Group0.730-0.010
Yangzijiang Shipbldg1.020-0.040

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 836 guests and one member online

  • admin2